Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma Who Refused Chemotherapy: an Open, Single-arm, Single-center Clinical Trial

NCT03728374 is registered in ClinicalTrials.gov with First Affiliated Hospital of Wenzhou Medical University as lead sponsor.

NCT NCT03728374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03728374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma Who Refused Chemotherapy: an Open, Single-arm, Single-center Clinical Trial
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2018
Completion date
November 1, 2020
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer